Mostrar el registro sencillo del ítem

Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.

dc.rights.licenseopenen_US
atmire.cua.enabled
dc.contributor.authorPOULLENOT, Florian
dc.contributor.authorOLLIVIER, Julien
dc.contributor.authorRIVIÈRE, Pauline
dc.contributor.authorSAUVAGET, Lucie
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorBERRONEAU, Aude
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorDJABAROUTI, Sarah
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorXUEREB, Fabien
dc.contributor.authorZERBIB, Frank
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorBREILH, Dominique
dc.contributor.authorLAHARIE, David
dc.date.accessioned2021-02-02T14:59:57Z
dc.date.available2021-02-02T14:59:57Z
dc.date.issued2020-01-01
dc.identifier.issn1878-3562en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26094
dc.description.abstractEnAccording to infliximab (IFX) license in Crohn's disease (CD), infusion doses are based on patient's body-weight. Dose banding providing standardized doses (SD) has been implemented in parenteral chemotherapy in order to optimize aseptic unit capacity and reduce drug expenditure, duration of hospital stay and costs without decreasing efficacy. The first part was a single-center retrospective analysis of consecutive CD patients receiving IFX maintenance therapy to determine standardized doses covering more than 50% of infusions. The second part was a prospective cohort study assessing the impact of SD compared to body-weight doses (BWD) on admission duration and costs. Six IFX SD covering more than 90% of infusion doses were implemented for dose banding. According to the Monte-Carlo simulation, there was no significant difference between IFX SD and BWD maintenance regimens. When assessed prospectively in 116 patients (75 patients treated with SD and 41 with BWD) corresponding to 128 infusions, hospitalization duration was shortened by 70 min per patient (p < 0.001). According to a pharmacokinetic model, IFX SD has a pharmacokinetic profile close to BWD and is associated with reduced length of hospitalization in a cohort of patients with CD. IFX SD implementation could optimize infusion units functioning and, save time and costs without decreasing efficacy.
dc.language.isoENen_US
dc.subject.enCrohn’s disease
dc.subject.enDose banding
dc.subject.enInfliximab
dc.subject.enModelling
dc.subject.enMonte-Carlo simulation
dc.subject.enPharmacokinetic
dc.title.enImplementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.
dc.title.alternativeDig Liver Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.dld.2019.11.018en_US
dc.identifier.pubmed31874834en_US
bordeaux.journalDigestive and Liver Diseaseen_US
bordeaux.page408-413en_US
bordeaux.volume52en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires - U1034en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.exportfalse
workflow.import.sourcepubmed
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Digestive%20and%20Liver%20Disease&amp;rft.date=2020-01-01&amp;rft.volume=52&amp;rft.issue=4&amp;rft.spage=408-413&amp;rft.epage=408-413&amp;rft.eissn=1878-3562&amp;rft.issn=1878-3562&amp;rft.au=POULLENOT,%20Florian&amp;OLLIVIER,%20Julien&amp;RIVI%C3%88RE,%20Pauline&amp;SAUVAGET,%20Lucie&amp;BERRONEAU,%20Aude&amp;rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BMC_ Dig.Liver.Dis_2020_POULLE ...
Tamaño:
340.1Kb
Formato:
PDF
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem